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Abstract
Background. Cinacalcet rapidly normalizes serum
calcium and reduces intact parathyroid hormone
(PTH) levels in renal transplant patients with hyper-
calcaemia and persistent hyperparathyroidism. The
aim of this study is to evaluate the 6 months efficacy of
cinacalcet and the effect of cinacalcet withdrawal on
serum calcium and PTH in such patients. Furthermore,
the impact of cinacalcet on bone turnover and quality
of life was assessed.
Methods. Twelve renal allograft recipients with hyper-
calcaemia due to persistent hyperparathyroidism were
treated with cinacalcet for 26 weeks. Cinacalcet was
then withdrawn to check for recurrence of
hypercalcaemia.
Results. Cinacalcet maintained normocalcaemia in all
patients from week 4 to 26, and PTH significantly
decreased and remained suppressed. Serum phosphate
increased, whereas the serum calcium–phosphate
product remained unchanged. The excretion of calcium
and phosphate in the 24 h urine had tendency to
decrease. After cinacalcet was withdrawn, hypercal-
caemia recurred rapidly and PTH increased to baseline
values. Renal function remained stable, proteinuria
was unchanged and no allograft rejection was
observed. During treatment with cinacalcet, total and
bone-specific alkaline phosphatase increased, whereas
the urinary deoxypyridinoline–creatinine ratio did not
change significantly, suggesting enhanced bone forma-
tion. Quality of life assessed at weeks 10 and 26
remained unchanged compared with baseline.
Conclusions. In conclusion, continued treatment
with cinacalcet is required to maintain long-term
normocalcaemia and to suppress the enhanced
PTH production in renal transplant recipients with
persistent hyperparathyroidism.
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Introduction
Persistent hyperparathyroidism with subsequent
hypercalcaemia after renal transplantation occurs
frequently. These metabolic imbalances are evident
soon after renal transplantation and resolve in only
50% of patients 1 year after transplantation [1,2].
Persistent hyperparathyroidism is a risk factor for
bone loss after renal transplantation [3,4].
Furthermore, the high PTH levels in renal transplant
patients are associated with vascular calcifications
and correlate with inferior graft function in patients
with interstitial calcifications in renal allograft [5].
Hyperparathyroidism and/or hypercalcaemia are
also associated with depression and non-specific
psychological distress and can have a negative
impact on general quality of life [6]. Besides parathy-
roidectomy, there are only limited therapeutic options.
Most patients remain untreated because they
do not meet the currently accepted guidelines for
parathyroid surgery, or do not wish to undergo
parathyroidectomy.
In a previous study, we have shown that cinacalcet
effectively normalized serum calcium and reduced
intact PTH in the short term in renal transplant
patients with persistent hypercalcaemia [7]. The present
article describes the results of a prospective study to
investigate the efficacy and safety of a 6-month
treatment with cinacalcet. Furthermore, the effect of
cinacalcet withdrawal after 26 weeks of treatment and
the impact of cinacalcet on bone turnover and quality
of life was assessed.
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Patients and methods
Patient population
This prospective single-centre, open-label study was
performed in renal transplant recipients with persistent
hyperparathyroidism and normal stable allograft function.
Study approval was obtained from the local ethics commit-
tee, and all patients gave written, informed consent. Twelve
renal allograft recipients, six men and six women, aged 49–70
years with a dialysis vintage of 32 months (median, range
0–84 months) were enrolled. The patients were 28 months
(median, range 6–384 months) after renal transplantation
and the immunosuppressive regimes were as follows: four
patients were taking cyclosporine A (CyA) and mycopheno-
late (MMF), three patients CyA, MMF and prednisone (P),
two patients CyA and azathioprine (AZA), one patient
was taking tacrolimus and MMF, one patient tacrolimus,
MMF and P and one patient AZA and P. One patient was
switched form cyclosporine to tacrolimus at the discretion
of the treating physician at week 10. For all patients
taking steroids, the administered doses of prednisone were
10mg/day. Preliminary results of 11 of these patients were
published elsewhere [7].
Study design
Inclusion criteria included renal transplantation at least
6 months before the start of cinacalcet treatment, stable
graft function with a calculated glomerular filtration rate
according to the modification of diet in renal disease study
group (MDRD GFR; extended version) 40ml/min/1.73m2,
persistently elevated serum calcium >2.60mmol/l (normal
range 2.10–2.60mmol/l) measured at least twice within
6 months before cinacalcet treatment started, plasma
intact PTH (iPTH) (Roche Diagnostics, Basel, Switzerland)
greater than 65 pg/ml (normal range 15–65 pg/ml) and
normal 25-hydroxyvitamin D3 (normal range 10–42mg/l)
and 1,25-dihydroxyvitamin D3 (normal range 19.9–67.0 ng/l)
levels. Total plasma calcium and phosphate levels were
recorded 3, 6 and 12 months prior to inclusion. Treatment
with diuretics, vitamin D sterols, calcium supplementation
and bisphosphonates or fluoride was not permitted during
the study period. Because cinacalcet inhibits P450 2D6
substantially, patients requiring drugs that are metabolized
by this enzyme and have a narrow therapeutic index (e.g.
flecainide, thioridazine and many tricyclic antidepressants)
were excluded. Patients received 30mg cinacalcet once daily
in the evening. The cinacalcet dosage was adapted in the
first 2 weeks of treatment to keep the serum calcium in the
predefined target range of 2.10–2.60mmol/l, independently
of PTH values. All patients continued to take the study
medications without interruption until week 26, except one
subject who discontinued after 2 weeks. At week 26,
cinacalcet was withdrawn, and the trial ended at week 30.
Study parameters
Blood samples were collected every 2 weeks for the
first 10 weeks and thereafter every 4 weeks. The following
values were measured: total and ionized calcium
(normal range 1.10–1.30mmol/l), phosphate (normal
range 0.87–1.45mmol/l), alkaline phosphatase (normal
value <129U/l) and bone-specific alkaline phosphatase
(normal range 3.4–21.1mg/l), creatinine (normal range male
70–105 mmol/l, female 60–90 mmol/l), urea (normal
value <11.9mmol/l), albumin (normal range 32–46 g/l) and
liver enzymes. Three different assays were performed to
evaluate PTH concentration: iPTH (Roche), iPTH (Nichols)
(normal range 10–65 pg/ml; Nichols Institute, San Juan
Capistrano, CA, USA) and bio-intact PTH (biPTH, normal
range 6–40 pg/ml; Nichols Institute, San Juan Capistrano,
CA, USA). Whole-blood trough levels of cyclosporine or
tacrolimus were also measured at each study visit. The
MDRD GFR was calculated by using the following values:
plasma creatinine, serum urea, serum albumin, gender, race
and age [8]. After a rest of 5min, sitting blood pressure was
measured at every study visit by an automatic blood pressure
monitor (Boso-Medicus, Jungingen, Germany).
Urine was collected over 24 h at week 0, 10 and 26 for the
measurement of creatinine clearance and fractional calcium
and phosphate excretion rates. At every visit, the spot urine
was analysed for protein/creatinine, albumin/creatinine
and deoxypyridinoline/creatinine ratios.
The quality of life was assessed at week 0, 10 and 26
using the self-rating SF-36 questionnaire, which measures
quality of life in various physical conditions [9]. For the
assessment of anxiety and depression, the Hospital Anxiety
and Depression Scale (HADS) [10,11], a 14-item self-rating
questionnaire, was used.
Statistical analysis
Means of continuous data were compared by the Student’s
t-test. P-values were two sided for the comparison with the
baseline value, and those <0.05 were considered statistically
significant. All results were expressed as means SE.
Linear regression analyses were performed for biPTH and
iPTH (Nichols), as well as biPTH and iPTH (Roche) from
week 0 to 30. Regression lines were fitted through the
intercept of biPTH and iPTH (Nichols), and biPTH and
iPTH (Roche), respectively. Mean comparisons of contin-
uous variables of SF-36 and HADS were tested using
Friedman’s test; categorical data were analysed with
Cochrane’s test. All tests were two-sided, and the significance
level was set at P< 0.05. Mood and quality of life data were
available for 10 patients. All analyses were performed using
SPSS software (version 12.0, SPSS Inc., Chicago, IL).
Results
Cinacalcet treatment normalizes total and ionized
calcium
At inclusion, all patients had hypercalcaemia and
persistent hyperparathyroidism. The baseline serum
calcium was 2.73 0.04mmol/l, the ionized calcium
was 1.40 0.02mmol/l and the PTH values were
elevated—iPTH (Roche) 190.3 26.1 pg/ml, iPTH
(Nichols) 266.6 43.1 pg/ml and biPTH 137.0
21.9 pg/ml. The initial 30mg cinacalcet dose was
adjusted within 2 weeks as follows: eight patients
remained at 30mg, one patient reduced to 15mg
and two patients increased to 60mg (one patient
was withdrawn after 2 weeks of treatment).
578 A. L. Serra et al.
After adjustment of the cinacalcet dose, total and
ionized serum calcium levels were maintained within
normal limits in all patients until week 26 (Figure 1). No
further cinacalcet dose adjustment had to be performed
later. Total calcium and ionized calcium were reduced
by 11.7 0.5 and 17.7 2.1% with a mean dose of
31mg/day cinacalcet after the dose-finding period.
Parallel reduction of bio-intact and intact PTH
during cinacalcet treatment
Plasma iPTH (Roche), iPTH (Nichols) and biPTH
were rapidly reduced during the dose-finding period,
with a maximal reduction after 8 weeks (by 32.2 6.0,
36.8 5.7 and 40.5 6.1%, respectively) and remained
suppressed until week 26 (Figure 2). Reductions
in biPTH paralleled reductions in iPTH throughout
the study (Figure 2). Regression analysis of biPTH
and iPTH (Roche) showed a highly significant
correlation (R¼ 0.981, P< 0.001). A similar significant
correlation (R¼ 0.982, P< 0.001) was observed
between biPTH (Nichols) and iPTH (Nichols). The
ratio of biPTH (Nichols) to iPTH (Roche) and biPTH
(Nichols) to iPTH (Nichols) was maintained at
52 0.3% and 49 2%, respectively, throughout
the study.
Fig. 1. Effect of cinacalcet on serum levels of total calcium, ionized calcium, phosphate and calcium–phosphate product. (A) Cinacalcet
normalized total serum calcium rapidly, and ionized calcium was below 1.35mmol/l in all patients from weeks 2 to 26. Hypercalcaemia
recurred after cinacalcet was withdrawn at week 26. Filled squares indicates total serum calcium, and filled triangles indicates ionized calcium.
(B) Cinacalcet increased mean serum phosphate significantly at week 2, 8, 10, 22 and 26. After cinacalcet withdrawal, serum phosphate
returned to baseline values. (C) The mean serum total calcium–phosphate product remained unchanged throughout. ***P< 0.001,
**P< 0.01, *P< 0.05, as compared with week 0 (meanSE).
Cinacalcet for persistent hyperparathyroidism 579
Impact of cinacalcet on serum phosphate and urinary
phosphate excretion
At inclusion, 58.3% of the patients were hypophos-
phataemic despite oral phosphate supplementation
in three of the 12 patients. Cinacalcet significantly
increased serum phosphate concentrations at study
week 2, 8, 10, 22 and 26, and oral phosphate
supplements could be stopped in all patients at
week 6 (Figure 1). At week 26, more than 90% of
the patients were normophosphatemic, and the lowest
individual serum phosphate level was 0.80mmol/l.
Fractional phosphate excretion measured after 10
and 26 weeks of treatment with cinacalcet had a
tendency to decrease compared with week 0 (Table 1).
The serum calcium–phosphate product remained
unchanged (Figure 1).
Cinacalcet withdrawal leads to recurrent
hypercalcaemia
After cinacalcet treatment was withdrawn, hyper-
calcaemia recurred, PTH values increased and serum
phosphate concentrations decreased to baseline level.
This shows that cinacalcet is necessary to maintain
normocalcaemia and to continuously suppress
enhanced PTH production in renal transplant
recipients with persistent hyperparathyroidism.
Renal function and calcineurin inhibitor trough
levels remain unchanged
Tables 1 and 2 show that renal allograft function
remained stable throughout the 6-month treatment
phase. Proteinuria (Table 2), albuminuria and blood
pressure (both data not shown) remained unchanged
and no allograft rejection was clinically suspected.
Table 2 shows also that cyclosporine doses and
cyclosporine trough levels remained unchanged
throughout the study. The switch from cyclosporine
to tacrolimus in one patient at week 10 led to a reduced
mean cyclosporine dose from weeks 14 to 30. The
cyclosporine trough levels remained unchanged
throughout the study. The doses of tacrolimus,
mycophenolate mofetil, azathioprine and prednisone
remained constant.
Influence of cinacalcet on biochemical markers
of bone metabolism
We also examined the effect of cinacalcet on biochem-
ical markers of bone turnover. At inclusion, the
alkaline phosphatase and bone-specific alkaline phos-
phatase were 92.2 10.8U/l and 20.45 3.8mg/l,
respectively. Alkaline phosphatase increased by
7.1 5.7% (P¼ ns) and 20.0 6.3% (P< 0.01), and
bone specific alkaline phosphatase by 9.8 5.7
(P< 0.01) and 19.5 4.8% (P< 0.01) from week 4
to 10 and 14 to 26, respectively (compared with
dose-finding period). Figure 3 shows that the
deoxypyridinoline/creatinine ratio in the spot urine
Fig. 2. Mean percentage change of biPTH and iPTH (Roche and
Nichols) compared with baseline values (100% value of week 0) over
time. (A) After cinacalcet dosage adaptation, mean percentage bio-
intact PTH (biPTH) was about 35% reduced compared with week 0.
(B) In parallel, mean percentage intact PTH (iPTH) (Nichols) and
(C) iPTH (Roche) were significantly reduced. After cinacalcet was
withdrawn, PTH values returned to baseline values. ***P< 0.001,
**P< 0.01, *P< 0.05, as compared with week 0 (mean SE).
Table 1. The 24 h urine analysis at study week 0, 10 and 26
Parameter Study week
0 10 26
CrCl (ml/min/1.73m2) 54.9 2.2 50.0 3.6 56.0 4.8
24 h urine Ca/Cr 0.43 0.11 0.36 0.10 0.26 0.06
FE Ca (%) 1.54 0.30 1.56 0.28 1.22 0.23
24 h urine P/Cr 3.00 0.43 2.50 0.19 2.68 0.21
FE P (%) 39.05 3.44 31.16 2.98 31.81 3.27
CrCl, measured creatinine clearance; Ca, calcium; Cr, creatinine;
FE, fractional excretion; P, phosphate.
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tended to increase (P¼ ns). Table 1 shows that
the fractional excretion of calcium and 24h urine calcium
to creatinine ratio had a tendency to decrease compared
with baseline values. The 25-hydroxyvitamin D3 and
1,25-dihydroxyvitamin D3 levels measured at week 0
(22.1 4.0mg/l, 43.6 4.0ng/l), 10 (16.9 1.9mg/l,
32.9 6.0ng/l) and 26 (21.8 3.2mg/l, 34.5 3.2ng/l)
remained in the normal range.
Effect on mood and quality of life
Using quality-of-life questionnaires (HADS and
SF-36), we examined the impact of cinacalcet treat-
ment on the patients’ well-being. On the depression
scale in the HADS, the score was 5.6 1.8, 4.9 1.6
and 5.7 1.5 and on the anxiety scale 6.0 1.5,
5.1 1.4 and 5.6 1.6 at week 0, 10 and 26,
respectively (cut-off for all scales: 8). All changes
were not significant using the Cochrane test. In the
SF-36, there were no changes between week 0, 10 and
26 for physical and mental health. The mean values for
both components of the SF-36 and all eight subscales
were within the norm at all three assessment points.
Adverse events
Overall cinacalcet was well tolerated, no specific side
effects were reported and no serious adverse events
occurred during the 26-week treatment phase. All
patients but one continued to take the study medica-
tions without interruption. As mentioned earlier, one
patient discontinued the study after 2 weeks because
she feared a possible deterioration of a pre-existing
retinitis pigmentosa. Ophthalmological examination
showed no changes in vision compared with pre-study
tests.
Discussion
Cinacalcet treatment was highly effective in rapidly
normalizing serum calcium and significantly reducing
PTH in renal transplant patients with chronic hyper-
calcaemia and persistent hyperparathyroidism. The
effect was sustained over 6 months, but reversed
Fig. 3. Mean percentage change of AP, BSAP and Dpyr/Crea ratio
during week 4 to 10 and 14 to 26 compared with dose-finding period.
(A) Cinacalcet increased alkaline phosphatase (AP) and (B) bone-
specific alkaline phosphatase (BSAP), expressed as mean percentage
of initial AP and BSAP (100% value of week 0). (C) The mean
percentage change of deoxypyridinoline/creatinine (Dpyr/Crea) ratio
remained unchanged. **P< 0.01, *P< 0.05, as compared with
dose-finding period (mean SE).
Table 2. Renal parameters, cyclosporine dose and whole-blood trough levels at study week 0, 10, 26 and 30
Parameter Study week
0 10 26 30
Serum creatinine (mmol/l) 116.1 8.7 128.2 10.7 127.6 11.1 124.0 9.0
MDRD GFR (ml/min/1.73m2) 56.0 4.8 49.9 4.5 50.4 3.5 51.2 4.2
Protein/Cr (mg/mmol) 14.1 2.5 7.9 2.8 11.4 3.3 9.9 3.2
Cyclosporine dose (mg/day) 188.9 13.9 193.8 14.8 162.5 26.3 162.5 26.3
Cyclosporine dose (mg/kg/day) 2.98 0.18 2.93 0.17 2.52 0.39 2.51 0.39
Cyclosporine trough level (mg/l) 110.0 12.9 117.6 10.1 111.6 6.5 111.0 11.7
MDRD GFR, calculated glomerular filtration rate according to the modification of diet in renal disease study group (extended version);
Cr, creatinine.
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rapidly when cinacalcet was stopped. Cinacalcet
treatment also corrected hypophosphataemia and
normalized serum phosphate in more than 90% of
the patients, without increasing the serum calcium–
phosphate product. These results confirm and extend
the findings of previous short-term studies with
cinacalcet in renal allograft patients with persistent
hyperparathyroidism [7,12].
Treatment with cinacalcet for 6 months did not
prevent recurrence of hypercalcaemia and PTH
increase to baseline values after cinacalcet was with-
drawn. It is known that the development of hyper-
calcaemia correlates with severity of the hyperplasia
and nodular transformation of the parathyroid
gland [13]. Although cinacalcet attenuates parathyroid
hyperplasia in a rat model of secondary hyperparathy-
roidism [14], and although successful renal transplan-
tation reverses hyperparathyroidism via involution of
the parathyroid glands in renal transplant patients [15],
the hyperfunctional potential of the parathyroid gland
often persists, and is only controlled as long as
cinacalcet is given. Therefore, cinacalcet needs to be
given continuously to control normocalcaemia in these
patients. We cannot exclude that longer treatment
duration (>6 months) may lead to permanent inhibi-
tion of parathyroid function in renal transplant
patients.
The PTH levels were measured by three different
methods, and all values decreased significantly by
approximately 25–35% after the dose-finding period.
It should be noted that these values represent hormone
concentrations 12 hours after the evening dose of
cinacalcet and may underestimate PTH reduction over
24 h. Pharmacodynamic data in patients with primary
hyperparathyroidism demonstrated that plasma PTH
levels were reduced by 60% from baseline 2 to 4 h after
dosing [16]. Regression analysis revealed statistically
significant correlation between the bio-intact assay and
two different intact PTH assays. Because the correla-
tion between plasma biPTH and iPTH was excellent,
we propose that full-length PTH can be reasonably
estimated by multiplying iPTH (Roche) by 0.52 and
iPTH (Nichols) by 0.49 in renal transplant patients
with persistent hyperparathyroidism. Several studies
have shown statistically significant correlations
between bio-intact and intact immunometric PTH
assays for patients with primary hyperparathyroidism
[17] and for patients with end-stage renal disease [18].
Similar strong correlations between PTH assays were
also reported in patients with ESRD during cinacalcet
treatment [19].
During the 26 weeks of treatment with cinacalcet,
renal allograft function remained stable. Infusion of
PTH is known to increase GFR and renal blood flow,
most likely through a hemodynamic effect [20].
Cinacalcet might, therefore, decrease GFR via its
PTH-lowering effect. But a conclusion on GFR
changes cannot be drawn from this study because
of the limited number of patients. Albuminuria and
proteinuria remained at a very low level in the spot
urine during the study. There was no allograft
rejection, and the blood pressure remained unchanged.
An important aim of our study was to exclude effects
of cinacalcet on CsA trough levels since in vivo
interaction data of cinacalcet with immunosuppressive
drugs are missing. The cyclosporine whole-blood
trough levels showed no relevant fluctuations, and
the dosage could be held constant. The cytochrome
P450 3A4 (CYP3A4) is the enzyme that is primarily
responsible for the elimination of cyclosporine and
tacrolimus. The CYP3A4 IC50 for cinacalcet is 100mM
(Amgen, internal data). That is 1000 times higher than
the highest unbound cinacalcet concentrations that
can be achieved clinically. Because cinacalcet mainly
inhibits CYP 2D6 and has a low inhibitory potential
for CYP3A4, no interactions with the metabolic
transformation of cyclosporine or tacrolimus were
expected. Indeed, we could not demonstrate an
effect of cinacalcet treatment on CsA trough levels.
Formal pharmacokinetic–pharmacodynamic studies
are needed to exclude subtle effects of cinacalcet on
CsA pharmacokinetics.
Persistent hyperparathyroidism, together with
steroid use, causes a decrease in bone density in renal
allograft patients [4]. Studies have shown decreased
levels of bone-specific alkaline phosphatase after
renal transplantation [21,22], reflecting decreased
osteoblast activity [23]. We found that cinacalcet
treatment increased alkaline phosphatase and bone-
specific alkaline phosphatase in renal allograft recipi-
ents. In patients with primary hyperparathyroidism,
cinacalcet treatment also increased bone-specific alka-
line phosphatase, and the urine deoxypyridinoline/
creatinine ratio remained unchanged compared with
placebo [16]. A possible explanation is that the cycling
PTH levels that are induced by cinacalcet treatment
may stimulate bone formation. Cinacalcet treatment
induces such cycling PTH levels in patients with
primary [16] and secondary hyperparathyroidism [24].
By analogy, daily PTH (1-34) injections have a
stimulatory effect on bone turnover [25]. Preliminary
evidence also suggests that cinacalcet increases bone
mineral density [26] and reduces the risk of fractures
[27] in patients with secondary hyperparathyroidism.
Altogether, our data suggest that cinacalcet stimulates
bone formation and may have a favourable effect
on bone metabolism. Further studies are needed
to confirm that cinacalcet has a beneficial effect
on the skeletal system in patients with persistent
hyperparathyroidism.
Depression and non-specific psychological symp-
toms are frequent in patients with hyperparathyroid-
ism and account for impaired quality of life in patients
after kidney transplantation. In our patients, five
out of 10 scored above the cut-off for depression
and/or anxiety before treatment. Although changes of
depression and anxiety scores are not significant, it is
remarkable that two of the five patients with anxiety
and/or depressive symptoms at week 0 were no longer
anxious or depressive after 26 weeks of treatment. Due
to the small sample size and the relatively low
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depression and anxiety scores, this improvement is not
statistically significant.
In conclusion, continued treatment with cinacalcet
maintains normocalcaemia and significantly reduces
PTH in renal transplant recipients with persistent
hyperparathyroidism. Cinacalcet appears to have
favourable effects on bone formation. Further studies
with larger patient samples and larger treatment
duration are needed to examine the effect of cinacalcet
on patient outcomes such as bone disease, cardio-
vascular morbidity and allograft function after renal
transplantation.
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